查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654380

美国医药市场规模、份额和趋势分析报告：按分子、产品类型、给药途径、疾病、年龄层、分销管道、细分预测，2025-2030 年

U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule, By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国医药市场规模及趋势

预计 2024 年美国医药市场规模为 6,343.2 亿美元，到 2030 年将达到 8,839.7 亿美元，2025 年至 2030 年的复合年增长率为 5.72%。这种增长是由于慢性病患病率上升、老龄人口增长、政府机构增加医疗保健支出以及普遍努力提高药品的可负担性和可获得性。

由于治疗方法的进步和强大的产品平臺，美国製药业正在经历强劲增长。标靶治疗、生技药品和个人化医疗的发展正在重塑治疗模式，并为癌症、自体免疫和遗传性疾病等复杂疾病提供更有效的解决方案。基因疗法和基于 RNA 的疗法正在获得 FDA核准，例如治疗遗传性视网膜疾病和某些癌症，有助于推动产业发展。用于治疗某些癌症的CAR-T细胞疗法等尖端药物的核准表明市场对精准医疗的关注度日益提高，为治疗以前无法治癒的疾病带来了希望。显着的进展包括免疫肿瘤疗法的持续进步，重新定义了癌症治疗。

在美国医药市场，GLP-1受体促效剂及GLP-1/GIP双重促效剂的突破性临床结果为肥胖治疗树立了新的标准。 GLP-1受体促效剂和GLP-1/GIP双重促效剂作为将带来前所未有的临床效果的突破性治疗方法而备受关注。这些药物，包括Semaglutide和替泽帕肽，已被证明可以使体重减轻高达 25%，远远超过先前只能达到 7% 左右减重效果的药物类别。这项突破重塑了患者和医疗保健提供者的肥胖治疗模式，为长期难以控制的疾病提供了可行的医疗解决方案。加上数位健康工具的进步，这些治疗现在已成为将药物治疗与技术、行为指导和个人化介入相结合的综合护理模式的一部分。这种综合方法不仅能解决肥胖问题，还能改善患者的整体治疗效果，为克服美国重大公共卫生挑战指明了方向。

美国医药品研究开发费用是市场成长的重要驱动力，该领域不断投资于发现和开发新的治疗方法。 2023年，美国製药公司在研发上的投入将超过800亿美元，而且这个数字每年都在增加。强生、默克、礼来等大公司认识到开发创新药物以应对人口老化和慢性病增加的重要性，并将公司收益的很大一部分用于研发。

如此高水准的投资正在推动肿瘤学、免疫学和罕见疾病等多个领域的突破性治疗方法的发现。根据牛津学术杂誌的报导，到2023年，美国的药品支出将增加13.6%，达到7,225亿美元。这一增长是由利用率增加 6.5%、新药增加 4.2% 以及价格上涨 2.9% 所推动的。 2023 年最畅销的药物是Semaglutide，其次是Adalimumab和Apixaban。此外，到 2023 年，非联邦医院的药品支出预计将下降 1.1% 至 371 亿美元，而诊所的药品支出将增加 15.0% 至 1,357 亿美元。诊所的成长是由利用率的提高所推动的，仅受到新产品和价格变化的轻微影响。对于非联邦医院，利用率降低导致支出降低，但新药和价格的影响很小。预计 2024 年将推出的几种新药将继续推动支出，尤其是在专科、内分泌和肿瘤治疗领域。

新型创新药物不断涌入市场也是美国医药市场发展的主要动力之一。随着患者和医疗保健提供者越来越意识到新疗法的有效性，对具有更好结果和更少副作用的最先进治疗的需求也日益增加。特别是生技药品、基因治疗、免疫治疗对癌症、自体免疫疾病等的应用日益广泛。例如，单株抗体（如用于免疫肿瘤学的抗体）的快速应用已经改变了治疗格局，市场领导者 Keytruda 和Opdivo 的与前一年同期比较实现了令人印象深刻的成长。近日，2024年9月，API研发中心接受了1,400万美元的战略资金，旨在加强美国製药独立性。这笔资金将支持美国关键活性药物原料药(API) 製造能力的发展，提高供应链的弹性并减少对海外来源的依赖。这项倡议符合加强国内生产、提高国家安全和确保持续获得​​基本药物的努力。

然而，主要药物的专利到期是美国製药业发展的一大限制因素。当专利到期时，学名药往往会进入市场，导致品牌药销售量急剧下降。例如，2023年1月，艾伯维的重磅药物Humira（Adalimumab）的专利将到期，该药物年销售额超过200亿美元，为生物仿製药的竞争打开了大门。从品牌药物转变为学名药的转变将减少原产公司的市场占有率，从而严重影响其收益来源。整体市场动态也将受到学名药定价压力的影响，迫使原产公司降低价格或寻找新的市场利基。这种转变在生技药品市场尤为明显，其中Enbrel和Herceptin等主要产品的专利已到期，为更便宜的替代品铺平了道路。

目录

第 1 章美国医药市场：调查方法与范围

第 2 章美国医药市场：执行摘要

  • 市场概述
  • 段简介
  • 竞争格局概况

第 3 章美国医药市场的变数、趋势与范围

  • 市场区隔和范围
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 波特五力分析
  • PESTLE分析

第 4 章：美国医药市场按分子类型、展望、估计和趋势分析

  • 美国药物市场：分子类型变异分析
  • 生技药品和生物相似药（聚合物）
  • 传统药物（小分子）

第 5 章：美国医药市场：按产品分類的估计和趋势分析

  • 美国医药市场：产品波动分析
  • 品牌
  • 非专利的

第六章美国医药市场类型、估计与趋势分析

  • 美国医药市场：类型变化分析
  • 处方笺
  • 在商店

第 7 章美国医药市场：疾病展望、估计与趋势分析

  • 美国医药市场：疾病展望与趋​​势分析
  • 心血管疾病
  • 癌症
  • 糖尿病
  • 感染疾病
  • 神经系统疾病
  • 呼吸系统疾病
  • 自体免疫疾病
  • 精神疾病
  • 胃肠道疾病
  • 女性健康疾病
  • 遗传疾病及罕见遗传疾病
  • 皮肤病
  • 肥胖
  • 肾臟疾病
  • 肝臟疾病
  • 血液系统疾病
  • 眼部疾病
  • 不孕不育
  • 内分泌失调
  • 过敏
  • 其他的

第 8 章：美国药品市场按给药途径分類的估计和趋势分析

  • 美国医药市场：给药途径变化分析
  • 口服
  • 局部的
  • 肠外
  • 吸入
  • 其他的

第九章美国医药市场：按年龄组别分類的估计和趋势分析

  • 美国医药市场：基于年龄的趋势分析
  • 儿童和青少年
  • 成人
  • 老年人

第 10 章：美国医药市场分销管道组别、估计与趋势分析

  • 美国医药市场：通路组变化分析
  • 医院药房
  • 零售药局
  • 其他的

第十一章 竞争格局

  • 公司分类
  • 战略地图
    • 新产品发布
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 2024 年主要企业的市场占有率分析
  • 公司热图分析
  • 公司简介
    • F. HOFFMANN-LA ROCHE LTD
    • NOVARTIS AG
    • ABBVIE INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • MERCK &CO., INC.
    • PFIZER INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • SANOFI
    • GSK PLC.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
Product Code: GVR-4-68040-210-9

U.S. Pharmaceutical Market Size & Trends:

The U.S. pharmaceutical market size was estimated at USD 634.32 billion in 2024 and is expected to grow at a CAGR of 5.72% from 2025 to 2030, to reach an estimated value of USD 883.97 billion by 2030. This growth can be attributed to the rising prevalence of chronic diseases, increasing geriatric population, growing healthcare expenditure by government organizations, and extensive efforts to improve the affordability & accessibility of pharmaceuticals.

The U.S. pharmaceutical industry has experienced significant growth due to advancements in therapeutics and a robust product pipeline. The development of targeted therapies, biologics, and personalized medicine has reshaped treatment model, offering more effective solutions for complex conditions such as cancer, autoimmune diseases, and genetic disorders. Gene therapies and RNA-based treatments, like those for inherited retinal diseases and certain types of cancers, have gained FDA approvals, contributing to the industry's momentum. The approval of cutting-edge drugs such as CAR-T cell therapies for certain cancers exemplifies the market's growing focus on precision medicine, offering hope for previously untreatable conditions. A notable advancement is the continued progression in immuno-oncology treatments, which are redefining cancer care.

In the U.S. market for pharmaceuticals, the transformative clinical outcomes of GLP-1 receptor agonists and GLP-1/GIP dual agonists, have set a new benchmark for obesity treatment. As they are emerged as transformative therapies, delivering unprecedented clinical results. These medications, such as semaglutide and tirzepatide, have demonstrated weight loss of up to 25%, significantly outperforming earlier drug classes, which achieved only about 7% weight reduction. This breakthrough has reshaped the obesity treatment paradigm for both patients and providers, offering a viable medical solution to a condition long viewed as difficult to manage. Coupled with advances in digital health tools, these therapies are part of integrated care models that combine pharmacological treatments with technology, behavioral coaching, and personalized interventions. This comprehensive approach not only addresses obesity but also improves overall patient outcomes, presenting a credible pathway to overcoming a major public health challenge in the U.S.

Pharmaceutical R&D spending in the U.S. has been a pivotal driver of market growth, with the sector continuously investing in the discovery and development of new therapies. In 2023, pharmaceutical companies in the U.S. spent over USD 80 billion on R&D, a figure that continues to rise annually. Major companies like Johnson & Johnson, Merck, and Eli Lilly have earmarked significant portions of their revenues to R&D, recognizing the importance of developing innovative drugs to meet the demands of an aging population and the increasing prevalence of chronic diseases.

This high level of investment fuels the discovery of breakthrough therapies across various segments, including oncology, immunology, and rare diseases. According to an article by oxford Academic, in 2023, U.S. pharmaceutical spending rose by 13.6% to reach USD 722.5 billion. This increase was driven by a 6.5% rise in utilization, a 4.2% boost from new drugs, and a 2.9% uptick in prices. The top-selling drug of 2023 was semaglutide, followed by adalimumab and apixaban. Furthermore, In 2023, drug spending in nonfederal hospitals decreased by 1.1%, totaling USD 37.1 billion, while expenditures in clinics increased by 15.0% to USD 135.7 billion. Clinic growth was driven by higher utilization, with a minor impact from new products and price changes. In nonfederal hospitals, lower utilization led to reduced spending, while new drugs and prices had a modest influence. Several new drugs expected in 2024, especially in specialty, endocrine, and cancer treatments, will continue to drive spending.

The growing market adoption of innovative and modern medicines is another key driver of the U.S. pharmaceutical market. As patients and healthcare providers become more aware of the effectiveness of new treatments, there is an increasing demand for cutting-edge therapies that offer better outcomes and fewer side effects. The uptake of biologics, gene therapies, and immunotherapies in oncology, autoimmune diseases, and other areas has been particularly notable. For example, the rapid adoption of monoclonal antibodies, such as those used in immuno-oncology, has transformed the treatment landscape, with market leaders like Keytruda and Opdivo showing impressive year-on-year sales growth. Recently, in September 2024, the API Innovation Center received USD 14 million in strategic funding aimed at strengthening U.S. pharmaceutical independence. The funding will support the development of critical Active Pharmaceutical Ingredients (API) manufacturing capabilities within the U.S., enhancing resilience in the supply chain and reducing reliance on foreign sources. This initiative aligns with efforts to bolster domestic production, improve national security, and ensure consistent access to essential medicines.

However, Patent expiration of key pharmaceutical drugs has emerged as a significant restraint for the growth of the U.S. pharmaceutical industry. Once patents expire, generic versions of these drugs can enter the market, often leading to a sharp decline in sales for the original branded drugs. For instance, in January 2023, the patent for AbbVie's blockbuster drug Humira (adalimumab), which generated over USD 20 billion in annual sales, expired, allowing biosimilars to compete. The shift from branded to generic drugs reduces the market share of originator companies and significantly impacts their revenue streams. The overall market dynamics are also affected by the pricing pressure brought on by these generics, forcing branded companies to reduce prices or find new market niches. This change is particularly evident in the biologics market, where patents for key products like Enbrel and Herceptin have expired, opening the door for cheaper alternatives.

U.S. Pharmaceutical Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. pharmaceutical market report based on molecule, product, type, disease, route of administration, age group, and distribution channel:

  • Molecule Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Biologics & Biosimilars (Large Molecules)
    • Monoclonal Antibodies
    • Vaccines
    • Cell & Gene Therapy
    • Others
  • Conventional Drugs (Small Molecules)
  • Product Outlook (Revenue, USD Billion, 2018 - 2030)
  • Branded
  • Generic
  • Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Prescription
  • OTC
  • Disease Outlook (Revenue, USD Billion, 2018 - 2030)
  • Cardiovascular diseases
  • Cancer
  • Diabetes
  • Infectious diseases
  • Neurological disorders
  • Respiratory diseases
  • Autoimmune diseases
  • Mental health disorders
  • Gastrointestinal disorders
  • Women's Health Diseases
  • Genetic and Rare genetic diseases
  • Dermatological conditions
  • Obesity
  • Renal diseases
  • Liver conditions
  • Hematological disorders
  • Eye conditions
  • Infertility conditions
  • Endocrine disorders
  • Allergies
  • Others
  • Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
  • Oral
    • Tablet Capsule
    • Suspensions
    • Other
  • Topical
  • Parenteral
    • Intravenous
    • Intramuscular
  • Inhalations
  • Other
  • Age Group Outlook (Revenue, USD Billion, 2018 - 2030)
  • Children & Adolescents
  • Adults
  • Geriatric
  • Distribution Channel Group Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Table of Contents

Chapter 1. U.S. Pharmaceutical Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Objectives
    • 1.3.1. Objective - 1
    • 1.3.2. Objective - 2
    • 1.3.3. Objective - 3
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. U.S. Pharmaceutical Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing healthcare spending by the government
      • 3.2.1.2. Improving affordability driven by rising per capita income
      • 3.2.1.3. Increasing awareness about healthcare among the population
      • 3.2.1.4. Increasing access to innovative and modern medicines
      • 3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
      • 3.2.1.6. Rising chronic diseases and geriatric population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. COVID-19 pandemic
      • 3.2.2.2. Intensification of competition from generic and biosimilar drugs
      • 3.2.2.3. Increasing price-sensitivity of customers for non-reimbursed drugs
      • 3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
  • 3.3. Porter's Five Forces Analysis
  • 3.4. PESTLE Analysis

Chapter 4. U.S. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis

  • 4.1. Molecule Type Outlook: Movement Analysis
  • 4.2. Biologics & Biosimilars (Large Molecules)
    • 4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.1.1 Biologics & Biosimilars (Large Molecules)
      • 4.2.1.2 Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
        • 4.2.1.2.1 Monoclonal Antibodies
        • 4.2.1.2.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.3.1 Vaccines
      • 4.2.3.2 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
        • 4.2.3.1.1 Cell & Gene Therapy
        • 4.2.3.3.2 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.5.1 Others
      • 4.2.5.2 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3. Conventional Drugs (Small Molecules)
    • 4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Pharmaceutical Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Pharmaceutical Market: Product Movement Analysis
  • 5.2. Branded
    • 5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Generic
    • 5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Pharmaceutical Market: Type Estimates & Trend Analysis

  • 6.1. U.S. Pharmaceutical Market: Type Movement Analysis
  • 6.2. Prescription
    • 6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3. OTC
    • 6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. U.S. Pharmaceutical Market: Disease Outlook Estimates & Trend Analysis

  • 7.1. U.S. Pharmaceutical Market: Disease Outlook Movement Analysis
  • 7.2. Cardiovascular diseases
    • 7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Cancer
    • 7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Diabetes
    • 7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Infectious diseases
    • 7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Neurological disorders
    • 7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Respiratory diseases
    • 7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. Autoimmune diseases
    • 7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.9. Mental health disorders
    • 7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.10. Gastrointestinal disorders
    • 7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.11. Women's Health Diseases
    • 7.11.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.12. Genetic and Rare genetic diseases
    • 7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.13. Dermatological conditions
    • 7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.14. Obesity
    • 7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.15. Renal diseases
    • 7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.16. Liver conditions
    • 7.16.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.17. Hematological disorders
    • 7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.18. Eye conditions
    • 7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.19. Infertility conditions
    • 7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.20. Endocrine disorders
    • 7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.21. Allergies
    • 7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.22. Others
    • 7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. U.S. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. U.S. Pharmaceutical Market: Route of Administration Movement Analysis
  • 8.2. Oral
    • 8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Topical
    • 8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Parenteral
    • 8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 8.4.1.1. Intravenous
      • 8.4.1.2. Intramuscular
  • 8.5. Inhalations
    • 8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Other
    • 8.6.1. Other Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. U.S. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 9.1. U.S. Pharmaceutical Market: Age Group Movement Analysis
  • 9.2. Children & Adolescents
    • 9.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3. Adults
    • 9.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4. Geriatric
    • 9.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. U.S. Pharmaceutical Market: Distribution Channel Group Estimates & Trend Analysis

  • 10.1. U.S. Pharmaceutical Market: Distribution Channel Group Movement Analysis
  • 10.2. Hospital Pharmacy
    • 10.2.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.3. Retail Pharmacy
    • 10.3.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.4. Others
    • 10.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
  • 11.2. Strategy Mapping
    • 11.2.1. NEW PRODUCT LAUNCH
    • 11.2.2. PARTNERSHIPS
    • 11.2.3. ACQUISITION
    • 11.2.4. COLLABORATION
    • 11.2.5. FUNDING
  • 11.3. Key Company Market Share Analysis, 2024
  • 11.4. Company Heat Map Analysis
  • 11.5. Company Profiles
    • 11.5.1. F. HOFFMANN-LA ROCHE LTD
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Financial Performance
      • 11.5.1.3. Product Benchmarking
      • 11.5.1.4. Strategic Initiatives
    • 11.5.2. NOVARTIS AG
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Financial Performance
      • 11.5.2.3. Product Benchmarking
      • 11.5.2.4. Strategic Initiatives
    • 11.5.3. ABBVIE INC.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Financial Performance
      • 11.5.3.3. Product Benchmarking
      • 11.5.3.4. Strategic Initiatives
    • 11.5.4. JOHNSON & JOHNSON SERVICES, INC.
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Financial Performance
      • 11.5.4.3. Product Benchmarking
      • 11.5.4.4 Strategic Initiatives
    • 11.5.5. MERCK & CO., INC.
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Financial Performance
      • 11.5.5.3. Product Benchmarking
      • 11.5.5.4. Strategic Initiatives
    • 11.5.6. PFIZER INC.
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Financial Performance
      • 11.5.6.3. Product Benchmarking
      • 11.5.6.4. Strategic Initiatives
    • 11.5.7. BRISTOL-MYERS SQUIBB COMPANY
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Financial Performance
      • 11.5.7.3. Product Benchmarking
      • 11.5.7.4. Strategic Initiatives
    • 11.5.8. SANOFI
      • 11.5.8.1. Company Overview
      • 11.5.8.2. Financial Performance
      • 11.5.8.3. Product Benchmarking
      • 11.5.8.4. Strategic Initiatives
    • 11.5.9. GSK PLC.,
      • 11.5.9.1. Company Overview
      • 11.5.9.2. Financial Performance
      • 11.5.9.3. Product Benchmarking
      • 11.5.9.4. Strategic Initiatives
    • 11.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 11.5.10.1. Company Overview
      • 11.5.10.2. Financial Performance
      • 11.5.10.3. Product Benchmarking
      • 11.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Pharmaceutical Market, By Disease, 2018 - 2030 (USD Billion)
  • Table 7 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 8 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 9 U.S. Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain-Based Sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 U.S. Pharmaceutical Market Segmentation
  • FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • FIG. 11 Penetration & Growth Prospect Mapping
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 U.S. Pharmaceutical Market: Product outlook and key takeaways
  • FIG. 15 U.S. Pharmaceutical Market: Product movement analysis & market share 2024 & 2030
  • FIG. 16 Branded U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 17 Generics U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 18 U.S. Pharmaceutical Market: Type outlook and key takeaways
  • FIG. 19 U.S. Pharmaceutical Market: Type movement analysis & market share 2024 & 2030
  • FIG. 20 Prescription U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 21 OTC U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 22 U.S. Pharmaceutical Market: Therapeutic category outlook and key takeaways
  • FIG. 23 U.S. Pharmaceutical Market: Therapeutic category movement analysis & market share 2024 & 2030
  • FIG. 24 Oncology U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 25 Anti-infectives U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 26 Cardiovascular diseases U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 27 CNS disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 28 Metabolic disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 29 GI disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 30 Respiratory diseases U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 31 Others U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 32 U.S. Pharmaceutical Market: Formulation outlook and key takeaways
  • FIG. 33 U.S. Pharmaceutical Market: Formulation movement analysis & market share 2024 & 2030
  • FIG. 34 Tablets U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 35 Capsules U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 36 Injectables U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 37 Sprays U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 38 Suspensions U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 39 Powders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 40 Others formulation U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 41 U.S. Pharmaceutical Market: Age group outlook and key takeaways
  • FIG. 42 U.S. Pharmaceutical Market: Age group movement analysis & market share 2024 & 2030
  • FIG. 43 Children & Adolescents U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 44 Adults U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 45 Geriatric U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)